Management of the idiopathic inflammatory myopathies

Nadin, Tom; Haque, Ashraful; Akil, Mohammed; Hughes, Michael

doi:10.1002/psb.1762

Cited by 6 publications

(4 citation statements)

References 14 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dermatomyositis (DM) and polymyositis (PM) are rare, chronic autoimmune connective tissue diseases within the spectrum of the idiopathic inflammatory myopathies (IIMs). 1,2 These conditions are associated with significant disease-related morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

“…1 Disease pathogenesis is complex and incompletely understood; however, ultraviolet radiation (UV) has been implicated in the pathogenesis of DM. 1,4 Treatment is with immunosuppressive medication including glucocorticoids, disease-modifying agents (eg methotrexate and mycophenolate), and often intensive/targeted therapies (eg cyclophosphamide and rituximab). 1,5 However, establishing the diagnosis of IIMs can be challenging, including due to the rarity and heterogeneous manifestations of the spectrum of disease.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…The incidence and prevalence of IIMs range from 1.16 to 19 per million and 2.4 to 33 per 100 000, respectively, 3 and with a peak age at diagnosis between 45 and 60 years 1 . Disease pathogenesis is complex and incompletely understood; however, ultraviolet radiation (UV) has been implicated in the pathogenesis of DM 1,4 . Treatment is with immunosuppressive medication including glucocorticoids, disease‐modifying agents (eg methotrexate and mycophenolate), and often intensive/targeted therapies (eg cyclophosphamide and rituximab) 1,5 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of internet‐based information on dermatomyositis and polymyositis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Aim: Patients with rheumatic diseases are increasingly using internet-based information to inform healthcare utilization and make treatment decisions. Our aim was to assess the readability and quality of internet-based information on dermatomyositis (DM) and polymyositis (PM). Method: Key words "Dermatomyositis" and "Polymyositis" were searched on 3 commonly used search engines (Google, Yahoo and Bing). The first 3 pages (~30) of search results were examined from each search engine. Readability of information was assessed using 4 readability formulae (Flesch Reading Ease Score, Flesch-Kincaid Grade Level, the Simplified Measure of Gobbledygook index, the Coleman-Liau index). Quality of information was assessed using the DISCERN tool, Journal of The American Medical Association (JAMA) benchmark criteria and Health on The Net Code (HoN code). We also examined Google Trends ® data to determine if there were obvious temporal search patterns. Results: Thirty-two websites were included in the study after duplicates were removed and exclusion criteria were applied. The overall quality was low including DISCERN with a median overall score of 38/80 (interquartile range 12.25), only 4/32 (13%) websites fulfilled all 4 JAMA benchmark criteria, and 9/32 (28%) had HoN code. Readability of information was assessed using 4 readability formulae (Flesch Reading Ease Score, Flesch-Kincaid Grade Level, the Simplified Measure of Gobbledygook index, the Coleman-Liau index. There was no obvious temporal trend in searches on analysis of Google Trends ® data. Conclusion: The overall quality and readability of internet-based information relating to DM and PM is poor. Patients require appropriate information of high quality and readability throughout the course of their disease in order to make informed decisions on their condition including treatment.

show abstract

Section: Introductionmentioning

confidence: 99%